Become A Featured Company

Tetra BioPharma (GRPOF): Standing on the Right Side of Regulation (Plus New Interview)

Ryan Allway

January 17th, 2017

News, Top News

The cannabis industry could reach $50 billion in annual revenue by 2026, according to Cowen & Co., but capitalizing on the drug’s enormous potential is not easy.

The United States government has permitted individual states to legalize the drug, but the Drug Enforcement Administration recently cracked down on cannabidiol (CBD) makers and President Trump’s cabinet picks are opponents of legalization. In Canada, voters approved the nationwide legalization of cannabis with the election of Prime Minister Trudeau, but the framework governing the program is only now starting to become clear.

In this article, we will look at how Tetra Bio-Pharma Inc. (OTC: GRPOF) (CSE: TBP) (CN: TBP) has positioned itself on the right side of regulations in both markets with its unique approach.

Evolving Cannabis Regulations

The Canadian Cannabis Task Force recently made 80 recommendations to the government regarding the legalization of cannabis. These recommendations covered topics ranging from home cultivation requirements to how medical cannabis can be prescribed by doctors and consumed by patients. These recommendations will be instrumental in helping the Trudeau administration implement the final rules governing the burgeoning industry.

Dr. Chamberland points out that medical cannabis patients are keen on receiving reimbursements since they cannot afford regular access without it. At the same time, physicians have been hesitant to prescribe medical cannabis without robust clinical trials demonstrating both safety and efficacy. These demands could lead to a much more ‘pharmaceutical’ approach than existing medical cannabis programs.

Prescriptions & Clean Supplements

Tetra Bio-Pharma has already started down the pharmaceutical path by undergoing clinical trials for medical cannabis in its natural form. The company believes that smokable marijuana may provide patients with a better natural alternative to synthetic cannabinoids and extracts developed by companies like GW Pharmaceuticals plc (NASDAQ: GWPH). With the large number of existing users, the company also has access to a lot of data to support its clinical studies.

The company’s PPP001 clinical studies involve the use of a titanium pipe that is classified as a medical device and blister packs containing dried cannabis pellets that are smoked to deliver the active ingredients via inhalation. Currently, the company is awaiting guidance from the Center for Drug Evaluation Research after a referral from the U.S. Food & Drug Administration. The company’s two other programs are focused on insomnia (PPP002) and neurological conditions (PPP003).

Finally, the company is developing over-the-counter products that side step the DEA’s concerns over CBD being in supplements. In the interview above, Dr. Chamberland stressed that the company’s OTC products are being developed without CBD or THC, but still include many other cannabinoids as active ingredients. These other cannabinoids are often ignored due to their low concentrations, but could offer benefits in many different areas.

Looking Ahead

Tetra Bio-Pharma Inc. (OTC: GRPOF) (CSE: TBP) (CN: TBP) has managed to develop a strategy that plays nicely with new regulations surrounding the cannabis industry in the United States and Canada. With its focus on prescription drug development, the company aims to develop products that patients and doctors can be confident in as early as next year. The company is also developing THC and CBD-free over-the-counter products to generate near-term revenue.

For more information, visit the company’s website at www.tetrabiopharma.com or visit CannabisFN.com’s profile at www.cannabisfn.com/mdc/tetra-biopharma/.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading